Dragon Ball's Frieza has an abundance of transformations, some of which showcase some especially impressive design aesthetics ...

Piccolo is far more powerful than any other Namekian in Dragon Ball, but there are still plenty who wield incredible strength ...

Dragon Ball Daima concludes the story with King Gomah ... we find out that the previous Demon Kings had a third eye, which granted them unparalleled strength. It was lost before Dabura became ...

Availability: Eternal Voyager was only available as part of the Season X Battle Pass, so is no longer available in its original form ... The crossover with Dragon Ball Super is another standout ...

“Giant Gomah” might not be the most creative name for Gomah’s new Evil Third Eye infused form (which also has ... as it had been teased with Dragon Ball Daima. It boosted Gomah’s magic ...

but Gohan hasn't grown at all since his victory over Perfect Cell. It's a revelation that eventually leads him on a path to discovering a new form — Ultimate Gohan. Dragon Ball Super Volume 24's ...

Organelles in cells were originally often independent cells, which were incorporated by host cells and lost their ...

When Dragon Ball Daima was announced, fans were expecting it to be a pointless project, but their opinion quickly changed once the anime began airing. In next to no time, they realized it wasn't ...

Akira Toriyama's final project, Dragon Ball Daima, concluded on February 28, 2025, coinciding with his first death anniversary. The show introduced mysterious artifacts, hinting at future stories.

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...

(MENAFN- Investor Brand Network) Toyota Motor Corporation has taken another bold step toward a hydrogen-powered future with the launch of its third-generation fuel cell (3rd Gen FC) system.

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...